CARLSBAD, Calif., Feb. 24 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announcedtoday that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.
The featured four-part series in The New York Times, this week focuses
Melanoma is the most serious type of skin cancer with about 70,000 new melanoma cases diagnosed every year in the USA and about 160,000 worldwide. When diagnosed early melanoma is curable, however advanced stage disease has carried a poor prognosis up to now.
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All